ライフサイエンスコーパス: age at

1 ty of blood-borne macrophages decreased with age at 18 months in the wild-type mouse.

2 rom healthy nonobese children </=18 years of age at 19 centers with a normal echocardiogram included

3 utritional outcomes in children under 5 y of age at 6 mo and at 1 y.

4 between relative age within the school year, age at ADHD diagnosis, and year of diagnosis (1998-2003

5 75 boys [70.1%] and 32 girls [29.9%]; median age at AIS, 7.7 years [interquartile range, 3.1-13.6 yea

6 466 901 men and women (mean age at baseline 56.5 years [SD 8.1]) were included in th

7 Estimation Algorithm) software, adjusted for age at baseline data collection.

8 of employed men and women 18 to 74 years of age at baseline examination in 1967 to 1973.

9 male participants between 20 and 60 years of age at baseline of the population-based Doetinchem Cohor

10 The mean (SD) age at baseline was 25 (3.6) years, 49% (n = 2066) of th

11 Among the 85 patients with ARVD/C, mean (SD) age at baseline was 42.8 (14.4) years and 47 (55%) were

12 Among the 115 patients, the mean (SD) age at baseline was 67.4 (10.1) years, 63 were men (54.8

13 ndividuals, 111 (72.1%) were male; mean (SD) age at baseline was 7.15 (2.19) years.

14 Mean (SD) age at baseline was 9.0 (2.3) weeks; 3906 (51.2%) were b

15 patients (43 males and 19 females; mean [SD] age at biopsy, 61.6 [13.7] years), 89.9% (124 of 138) we

16 P) model uses birth weight (BW), gestational age at birth (GA), and weight gain rate to predict the r

17 sion (sRRR) and correcting for ethnicity and age at birth and imaging.

18 To test whether advanced maternal age at birth independently increases the risk of low bir

19 patient charts including gender, gestational age at birth, birthweight, stage of ROP at presentation,

20 re- and early postpartum stress, gestational age at birth, infant sex, and postnatal age at magnetic

21 d by exposure to HIV and size or gestational age at birth.

22 mong infants less than 33 weeks' gestational age at birth.

23 events persists over time, though increasing age at cancer diagnosis and treatment with hormonal ther

24 We compared the median age at cancer diagnosis between PLWH in the North Americ

25 We also compared median age at cancer diagnosis by AIDS status and CD4 count.

26 In total, 12428 patients (mean (SD) age at cancer diagnosis, 75 (7) years; 52.0% female) wer

27 Age at cancer diagnosis.

28 Median age at cataract surgery was 2.2 months (interquartile ra

29 High parental age at childbirth has repeatedly been linked to childhoo

30 inopathy of prematurity occurrence, maternal age at childbirth, mother smoking, breastfeeding < 3 mon

31 height, weight, pack-years, current smoking, age at completed full-time education, spirometer, and in

32 In humans, the effect of paternal age at conception (PAC) on offspring leukocyte telomere

33 used multivariate regression to control for age at death and sex.

34 ed individuals of known period of burial and age at death is described.

35 orrelation between osteocytes per lacuna and age at death may reflect reported age-related responses

36 We used dental histology to estimate the age at death to be 7.7 years.

37 re women and 158 were men, and the mean (SD) age at death was 90.4 (6.0) years.

38 se onset until death or last examination, or age at death was collected for for 244 individuals (132

39 Three boys (median age at death, 12 years; range, 9-13 years) who received

40 202 deceased former football players (median age at death, 66 years [interquartile range, 47-76 years

41 ically diagnosed in 177 players (87%; median age at death, 67 years [interquartile range, 52-77 years

42 t variables on each outcome: sex, ethnicity, age at death, index of multiple deprivation quintile, ye

43 .003; 0.15, <0.0001) in models that included age at death, sex, cerebral neuritic plaque scores, cere

44 ffect on age at onset, disease duration, and age at death.

45 evelops as specific patterns with respect to age at debut, development over time, and involved allerg

46 h of birth during the same year, gestational age at delivery, Apgar score at 5 minutes, maternal and

47 id administration, preeclampsia, gestational age at delivery, days in intensive care unit, sex, age,

48 lms tumors with nephrectomy weight <550g and age at diagnosis <2 years) results in satisfactory event

49 is (1995-99, 2000-04, and 2005-09), sex, and age at diagnosis (<1, 1-4, 5-9, and 10-14 years, inclusi

50 rtile range, 30%-35%] predicted) and younger age at diagnosis (29 years; interquartile range, 23-38 y

51 and 157 men [45.0%]) had a similar mean (SD) age at diagnosis (69.6 [12.3] vs 66.1 [17.7] years).

52 ncreased by 24% with each 1-year increase in age at diagnosis (hazard ratio, 1.24; P = .0057).

53 Age at diagnosis and body site of melanoma.

54 f patients with AML who were >/= 66 years of age at diagnosis and diagnosed during the period from 19

55 Older age at diagnosis and poorer levodopa treatment response

56 ve study of the relationship between patient age at diagnosis and PTC-specific mortality with respect

57 Increasing age at diagnosis and report of having made an informed t

58 The mean (SD) age at diagnosis for the 65 057 women included in the an

59 giocarcinoma (n = 594); patients of advanced age at diagnosis had an increased incidence compared wit

60 Purpose For the past 65 years, patient age at diagnosis has been widely used as a major mortali

61 t study was designed to test whether patient age at diagnosis is a major mortality risk factor.

62 Mean (SD) age at diagnosis of any psychiatric disorder was 12.5 (8

63 model with systolic blood pressure (SBP) and age at diagnosis of hypertension, which was 2 to 5 years

64 Results Older age at diagnosis of stage III disease conveyed a worse p

65 Mean (SD) age at diagnosis of the 127 patients in the study (58 wo

66 every 5 years, beginning 10 years before the age at diagnosis of the youngest affected relative or ag

67 To investigate the effects of age at diagnosis on metastatic breast cancer and patient

68 fferences could reflect variation in patient age at diagnosis or ethnic variation affecting miRNA epi

69 mputed tomography, but a low Kco and a young age at diagnosis suggests the underlying molecular diagn

70 Median age at diagnosis was 12 years and median follow-up was 2

71 The mean age at diagnosis was 28.3 years and 60.6% of diagnosed p

72 Mean (+/- standard deviation) age at diagnosis was 40.9+/-16.9 years, and 64.6% of sub

73 The median age at diagnosis was 41 years; 75% were male, and 61% ha

74 Mean age at diagnosis was 46 years.

75 Median age at diagnosis was 63 years, including 599 patients (4

76 Age at diagnosis was an independent prognostic factor fo

77 stricted to younger patients (</=60 years of age at diagnosis).

78 and at age 6 years (i.e., closer to average age at diagnosis).

79 A total of 220 women were studied (mean [SD] age at diagnosis, 29.5 [6.6] years).

80 lack patients of African ancestry (mean [SD] age at diagnosis, 55.66 [13.01] years; 98.1% [n = 151] f

81 87 patients (1065 women, 1322 men; mean [SD] age at diagnosis, 58.3 [16.1] years) and 2917 primary me

82 ite patients of European ancestry (mean [SD] age at diagnosis, 59.51 [13.11] years; 99.0% [n = 768] f

83 s with ALS (168 women and 226 men; mean [SD] age at diagnosis, 60.18 [13.60] years) were observed in

84 Among survivors (median age at diagnosis, 62 years; 56% male), 115 were diagnose

85 omen [53.8%] and 3679 men [46.2%]; mean [SD] age at diagnosis, 66.4 [14.3] years) were included in th

86 nts with ALS (50 women and 66 men; mean [SD] age at diagnosis, 67.00 [10.74] years) identified throug

87 ng 23603 survivors of childhood cancer (mean age at diagnosis, 7.7 years; 46% female) the most common

88 varies by cancer type, decade of diagnosis, age at diagnosis, and attained age remains uncertain.

89 stimated based on the annual incidence, mean age at diagnosis, and average life expectancy.

90 f-function mutations associated with younger age at diagnosis, and CKD was observed in all phenotypes

91 Data were stratified by sex, age at diagnosis, and diagnostic era (ie, diagnosis befo

92 The diagnostic yield, patient age at diagnosis, and medical effect in the group that u

93 were estimated using Cox models adjusted for age at diagnosis, diagnostic certainty, diagnostic delay

94 7 [7.7] years) and was associated with older age at diagnosis, male sex, poor initial levodopa treatm

95 unselected for high-risk features (eg, early age at diagnosis, personal/family history of cancer or p

96 linic-based setting without preselection for age at diagnosis, personal/family history, or MSI/MMR re

97 elations of mutant chloride current with the age at diagnosis, plasma chloride concentration and urin

98 ntly correlates with the phenotypes, such as age at diagnosis, plasma chloride concentration, and the

99 S rate varied significantly by stage, grade, age at diagnosis, primary site, and time period of diagn

100 variation in clinical course associated with age at diagnosis, sex, and ductal and IBD subtypes.

101 this population were reviewed with regard to age at diagnosis, sex, histologic subtype, and other tum

102 io on the basis of sex, primary tumour type, age at diagnosis, smoking status, chemotherapy drug clas

103 de, and melphalan by minimisation, balancing age at diagnosis, stage, MYCN amplification, and nationa

104 Multivariable analyses showed that older age at diagnosis, treatment era, and higher doses of bra

105 IDH3A variants, age at diagnosis, visual acuity, fundus appearance, visu

106 9 patients who were younger than 66 years of age at diagnosis, we randomly assigned 240 patients to r

107 ual conductance were associated with younger age at diagnosis.

108 l lymphoma who were younger than 66 years of age at diagnosis.

109 into early (</=55 years) or late (>55 years) age at diagnosis.

110 odestly younger ages, and also shows younger ages at diagnosis of oral cavity/pharynx and kidney canc

111 has also been found to be a modifier of the age at disease onset in frontotemporal dementia patients

112 erimental data suggest a correlation between age at disease onset, response to sodium channel blocker

113 Among respondents, mean age at donation was 43.6 +/- 10.6 years, 64% were women,

114 od disorder onset in the bipolar parent, and age at each visit, predicted new-onset BPSD.

115 The mean (SD) age at end of follow-up was 4.6 (0.40) years for the 613

116 Among 98015 participants, the mean (SD) age at enrollment in the study was 48.3 (9.8) years, 97.

117 residents had a median (interquartile range) age at enrollment of 2.6 (0.4-9.1) years; 358 (49.9%) we

118 (62.4%) were male, and the mean (SD) patient age at enrollment was 11.9 (3.5) years.

119 The mean age at enrollment was 68.6+/-9.6 years.

120 ned to systemic therapy) (77% female; median age at enrollment, 48 [interquartile range, 36-56] years

121 imaging at the time of enrollment (mean [SD] age at enrollment, 55.6 [10.9] years).

122 Among the 607 participants (mean [SD] age at enrollment, 57.5 [10.9] years), 334 (55.0%) were

123 tudy eyes; 60.2% women and 39.8% men; median age at enrollment, 70 years [range, 42-90 years]), the 3

124 n blocks of eight, stratified by gestational age at enrolment (17-25 weeks vs 26-34 weeks).

125 METHODS AND We included 3311 adults (median age at entry 22.6 years, 50.6% males) with CHD (49% simp

126 have been in each category of obesity and of age at entry and how much higher the mortality rates wou

127 Among 329 participants, the mean age at evaluation was 27.6 years, with a 21-year mean fo

128 Results Median age at evaluation was 37 years; median time since chemot

129 eries (28 female and 15 male), the mean (SD) age at examination was 2.1 (1.5) months.

130 LOAD), and 7001 cognitively intact controls (age at examination, >65 years) from the Alzheimer's Dise

131 rm children (19 girls and 33 boys; mean [SD] age at examination, 6.6 [0.1] years) and 45 children bor

132 orn at term (22 girls and 23 boys; mean [SD] age at examination, 6.6 [0.1] years).

133 and included in multivariable analysis: sex, age at examination, anisometropia, myopic and hyperopic

134 f the subjects to substantially older median age at exit.

135 h little information on risk modification by age at exposure, years since exposure or dose-rate.

136 s in the hematopoietic system independent of age at exposure.

137 The median gestational age at fetal MRI was 32.3 weeks of pregnancy (+/-2.3).

138 ticipants, 931 [45.5%] were women; mean (SD) age at first assessment was 62.56 (14.63) years.

139 of benign breast biopsy, and nulliparity or age at first birth (>/=30 years vs <30 years).

140 Similarly, variants associated with later age at first birth are associated with a longer maternal

141 ions were similar for race, age at menarche, age at first birth, family history, alcohol consumption,

142 is associated with fewer children and older age at first child whereas higher polygenic risk of ADHD

143 were in 3586 women with epilepsy; mean (SD) age at first delivery of the epilepsy cohort was 30.54 (

144 The effect of age at first dose on the immunogenicity of a 2-dose pedi

145 ronegative (GMC <150 mIU/mL) were derived by age at first dose.

146 1.4%) examined had eye abnormalities (median age at first eye examination, 31 days; range, 0-305 days

147 Of the 1471 children, the median age at first FS was 21 months (interquartile range [IQR]

148 Negative effects of earlier age at first measles vaccine dose persisted after the se

149 The impact of age at first melanoma was observed only in those younger

150 Reproductive factors (number of live births, age at first pregnancy, and total reproductive duration

151 included 26 614 visits for 6196 males; mean age at first registry visit was 17.7 years; and median w

152 action of the variances in longevity (5.9%), age at first reproduction (3.7%) and lifetime reproducti

153 in longevity, lifetime reproductive output, age at first reproduction and in the proportion of the l

154 ogen and progesterone receptor status, or by ages at first-term birth or diagnosis.

155 nfants (95%) with primary outcome data (mean age at follow-up, 20.7 [SD, 3.5] months; 42% female), de

156 Median age at genetic evaluation was 11 years; 20.7% of patient

157 The median age at HSCT was 7.5 years.

158 Gestational age, age at illness onset, exposure to environmental tobacco

159 met key DACA eligibility criteria (based on age at immigration and at the time of policy implementat

160 era from 35 children with proven CMA (median age at inclusion of 10 months) were analyzed retrospecti

161 tation in ambulatory patients >/=65 years of age at increased risk of stroke is significantly more li

162 Median (interquartile) age at index date was 47 (27) years; 408230 of total pat

163 2-90 and D(b)M187-195, was determined by the age at infection.

164 41 women with invasive breast cancer, median age at initial breast cancer diagnosis was 60.6 years (a

165 For this group of 14 patients, median age at initial diagnosis of Stargardt disease was 9.5 ye

166 ong 5453 youths with type 1 diabetes (median age at initial diagnosis, 11 years; interquartile range,

167 and 7233 youths with type 2 diabetes (median age at initial diagnosis, 19 years; interquartile range,

168 nd 23 [52%] female) aged 2 to 18 years (mean age at initial presentation, 28 months; range, 0-121 mon

169 t study, we investigated the associations of age at initiation of indoor tanning, duration of tanning

170 were male, 77% white persons, and the median age at last follow-up date was 11.5 years.

171 les in this case series, with a mean (range) age at last review of 37.1 (16-70) years.

172 Eligible participants were any patients aged at least 18 years who underwent percutaneous corona

173 Included studies also focused on adults aged at least 18 years with a sample size of at least 10

174 We recruited patients aged at least 18 years with biopsy-confirmed primary IgA

175 Participants who were aged at least 18 years with influenza and were at increa

176 lled trial, we recruited non-pregnant adults aged at least 18 years with newly or recently diagnosed

177 ed as moderate or severe by DSM-IV criteria, aged at least 18 years, and were able and willing to pro

178 Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activit

179 re patients with active rheumatoid arthritis aged at least 18 years, with four or more of 68 tender j

180 Eligible patients were aged at least 18 years, with more than 1000 IU/mL HCV RN

181 nt of lower than 30 x 10(9) platelets per L, aged at least 18 years, with refractoriness, ineligibili

182 m 1990-2006 consisted of 15,099 participants aged at least 20 years at baseline, among whom there wer

183 om 30 239 participants from the USA who were aged at least 45 years and enrolled in the Reasons for G

184 attainment, unauthorized absence, exclusion, age at leaving school, unemployment after leaving, and h

185 longer was associated with increased median age at loss of mobility milestones by 2.1-4.4 years and

186 oL (vs >/=500) was associated with a younger age at lung cancer diagnosis (difference = 4; P = .006).

187 onal age at birth, infant sex, and postnatal age at magnetic resonance imaging scan.

188 k and examined the role of indoor tanning in age at melanoma diagnosis.

189 Age at menarche among women with MS was generally lower

190 We observed an inverse association between age at menarche and MS risk.

191 e addressed the possible association between age at menarche and multiple sclerosis (MS), and results

192 e this method using the relationship between age at menarche and risk of breast cancer, with body mas

193 Our findings indicate that a young age at menarche may identify women at higher risk of GDM

194 before the data analyses with a mean +/- SD age at menarche of 11.9 +/- 0.7 y.

195 Age at menarche was reported at baseline in 2000 when wo

196 389 independent signals (P < 5 x 10(-8)) for age at menarche, a milestone in female pubertal developm

197 Associations were similar for race, age at menarche, age at first birth, family history, alc

198 oximately 7.4% of the population variance in age at menarche, corresponding to approximately 25% of t

199 For each 1-year increase in age at menarche, risk of MS was reduced by 13% (hazard r

200 yogurt intakes were associated with a later age at menarche.

201 to breast composition at Tanner stage 4 and age at menarche.A total of 515 Chilean girls are include

202 324 girls with data on prospective diet and age at menarche.The mean +/- SD breast FGV and percentag

203 Earlier age at menopause is widely considered to be associated w

204 Younger age at menopause was associated with a higher risk of DC

205 d anxiety, general psychosocial functioning, age at mood disorder onset in the bipolar parent, and ag

206 lity; psychosocial functioning; and parental age at mood disorder.

207 less than the 10th percentile of length for age at more than half their visits.

208 Many clinical characteristics of HD such as age at motor onset are determined largely by the size of

209 Characteristics included are age at multiple autoantibody positivity, sex, selected h

210 focusing on African Americans >/=50 years of age at multiple inner-city community sites in Baltimore,

211 defining event was associated with a younger age at myeloma diagnosis (difference = 4; P = .01), and

212 iance and 1.1% (p = 1.30e(-05)) for MDD with age at onset <18 years.

213 An earlier age at onset (AAO) has been associated with greater gene

214 to -0.14; P = .02) and in those with a later age at onset (beta, -0.11; 95% CI, -0.14 to -0.08; P < .

215 ample) that is significantly correlated with age at onset (p=2 x 10(-89)).

216 rrelated with each other (r=0.674), and with age at onset (TRACK-HD, r=0.315; REGISTRY, r=0.234).

217 2 repeat expansion by means of a decrease in age at onset across successive generations.

218 actinic dermatitis presents with an earlier age at onset and an inverted male to female ratio in pat

219 MDD patients with early age at onset and higher symptom severity have an increas

220 ith SARA were explained by disease duration, age at onset and the shorter abnormal repeat in the FXN

221 rabismus subtypes, indicating differences in age at onset and thereby implying differences in the und

222 ve generations), although the differences in age at onset are not entirely accounted for by repeat le

223 Among the 111 individuals with age at onset available (66 men and 45 women; mean [SD] a

224 ed at-risk relatives confirmed a decrease in age at onset in successive generations (P < .001).

225 nset rod-cone dystrophy, with a mean (range) age at onset of 12.1 (7-17) years.

226 females) had new-onset MDD, with a mean (SD) age at onset of 14.4 (2.0) years (range, 10-18 years).

227 nset rod-cone dystrophy, with a mean (range) age at onset of 29.7 (20-40) years, and 6 had an earlier

228 Age at onset of disease decreases with increasing polygl

229 damage-response and repair pathways and the age at onset of disease.

230 terval before antiepileptic drug withdrawal, age at onset of epilepsy, history of febrile seizures, n

231 Median age at onset of eye disease was 60 months and duration o

232 he expanded CAG tract in HTT correlates with age at onset of Huntington's disease and other trinucleo

233 mutated gene and type of mutation influence age at onset of Lynch syndrome-associated cancers.

234 ground strongly influenced the magnitude and age at onset of these effects.

235 statistical methods tailored to address the age at onset of various forms of G1D, associated manifes

236 n [SD] age, 57.2 [9.1] years), the mean (SD) age at onset per generation (from earliest-born to lates

237 After pediatric onset MS (POMS) diagnosis, age at onset younger than 15 years and DMD exposure decr

238 and lifetime psychiatric disorders, disorder age at onset, and disorder severity in a nationally repr

239 Generational effect on age at onset, disease duration, and age at death.

240 Age at onset, visual acuity survival time, visual acuity

241 patients with strong family history or early age at onset.

242 risk loci and 14 novel loci associated with age at onset.

243 were stratified using increasing/decreasing age-at-onset cutoffs; significant single nucleotide poly

244 Type of surgical repair and age at operation varied considerably, but no association

245 Age at operation was >30 days in one-half of the cases a

246 The age at presentation and presence of a heritable RB1 muta

247 Mean age at presentation was 32 years, with a 3:2 male-to-fem

248 Mean age at presentation was 41.8 (range 3.3-81.6) years.

249 h 2 rare variants had a trend toward younger age at presentation when compared with patients with a s

250 Hazard rates of AT across lifetime, age at presentation, and the time lapse between surgery

251 nesterase, bilirubin, type of primary tumor, age at radioembolization, hepatic tumor burden, presence

252 ified women by site and by their gestational age at randomisation (before week 26 and 0 days or at we

253 ths adjusted for level of encephalopathy and age at randomization.

254 In the GBT group, younger age at recruitment, higher total IgE, higher blood eosin

255 In the GBT + omalizumab group, younger age at recruitment, increased eosinophil number, recent

256 Median age at referral was similar for men (22.5 years; interqu

257 We used maternal age at reproduction, brood size and survival rates in co

258 1 overdiagnosis rates increase rapidly with age at screening.

259 ears was significantly associated with early age at sensitization.

260 s associated with enhancement included older age at SMILE procedure, greater preoperative MRSE, great

261 9] from online survey; 85 [60%] female; mean age at start of study, 53 [range, 8-83] years; 131 [93%]

262 ,171 nonobese children who were 5-8 years of age at study enrollment in the Southern California Child

263 sion that was frequency matched by decade of age at study entry.

264 Results Median age at study was 6 years (range, 2 to 20 years); 43.8% w

265 The median age at surgery was 3.3 years (interquartile range 2.7-5

266 Age at surgery, regardless of stimulation status, may be

267 ostic value was independent of the patient's age at surgery, the pathological tumor stage and presenc

268 The mean (SD) age at surgical procedure was 63 (5) years.

269 Patients' mean (SD) age at symptom onset was 4.4 (4.4) years.

270 The median age at TA diagnosis was 36 [25-47] years, and 276 patien

271 The mean age at the age 5 years follow-up visit was 5.0 +/- 0.1 y

272 nd 1974 was 42.94 (1.73) years and mean (SD) age at the beginning of follow-up for dementia in 1996 w

273 ncidence and cumulative incidence and median age at the detection of strabismus, overall and by subty

274 matched for date of birth, sex, and mother's age at the infant's birth.

275 We included 9 eyes; median age at the moment of the PPK was 14 years.

276 ants (5 females and 2 males) whose mean (SD) age at the most recent examination was 17.1 (3.9) years

277 The median (IQR) age at the second AGV was 68.0 (53.5-77.9) years.

278 Their median age at the time of cladribine therapy was 62 years (age

279 en [34.2%]; 805 white [99.9%]) with a median age at the time of first staged excision procedure of 65

280 re female; 33 (73%) were white; and the mean age at the time of laser treatment was 14.5 years (range

281 isks of revision surgery based on increasing age at the time of primary surgery.

282 er duration of illness (after accounting for age at the time of scanning) was associated with reduced

283 ldren of all ages; 5 (19%) were <6 months of age at the time of their first illness.

284 is Risk in Communities study (67-91 years of age) at the fifth study visit as follows: A (asymptomati

285 mpare the probability of a first live birth, age at time of birth, and time between diagnosis/referen

286 ly; 22 patients have become tolerant (median age at tolerance acquisition of 51 months) during the st

287 , white race (HR, 9.04; 95% CI, 6.20-13.18), age at transplant 50 years or older (HR, 2.77; 95% CI, 2

288 nine consecutive adult patients, with a mean age at transplant of 24 years (range, 17-50 years), unde

289 Among the 62 boys in this study (mean [SD] age at transplant, 8.37 [2.80] years; range, 4-16 years)

290 analysis was used to estimate influences of age at transplantation and attained posttransplant age o

291 e modelling approach that accounted for both age at transplantation and time since transplantation.

292 The median age at transplantation was 9 years, and the median follo

293 ng this age period in France irrespective of age at transplantation.

294 motor delay during early development (later age at walking), but they were less impaired on certain

295 s and interneurons were established, but the age at which cells are isolated influences the neurotran

296 as at risk of preterm birth, the gestational age at which magnesium sulphate treatment was given, the

297 roductive success is therefore gained at the age at which reproductive performance peaks.

298 whether associations differ according to the age at which the parental separation occurred and the pr

299 (HPV) infections can occur at all ages, the age at which women acquire their "causal" HPV infection

300 tional samples were used to characterize the ages at which self-reported African American (n = 4973),